Colon cancer breakthrough keeps patients cancer-free for nearly 3 years
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UCL reported zero recurrences after 33 months in the NEOPRISM‑CRC trial where patients received nine weeks of pembrolizumab before surgery.
- Pembrolizumab given for nine weeks pre‑surgery induced a complete or near‑complete response in 59% of stage 2/3 colorectal cancer patients.
- Personalized blood tests using circulating tumor DNA predicted treatment success, allowing early identification of responders.
Why it matters: Patients with high‑risk stage 2/3 colorectal cancer gain a 33‑month disease‑free window, while hospitals and insurers avoid the 25% relapse rate and costly chemotherapy, cutting treatment toxicity and expenses.
Ask SkimNews
